Page 14 - Pharma Sector News Today

Growth momentum continued in the March quarter of 2021-22 and even during the ongoing first quarter of the current fiscal, a FICCI survey noted

Foreign Direct Investment (FDI) equity inflows into India contracted marginally by 1 per cent to $58.77 billion during 2021-22

Indian manufacturers will soon have an opportunity to work with WHO’s COVID-19 Technology Access Pool and the Medicines Patent Pool for developing innovative therapeutics, vaccines and diagnostics against coronavirus.

Indian pharma companies enabled by their price competitiveness and good quality, have made global mark, with 60 per cent of the world’s vaccines and 20% of generic medicines coming from India.

Indian pharma exports witnessed a growth of 103 per cent since 2013-14

Indias pharma exports have witnessed a growth of 103 per cent since 2013-14 from Rs 90,415 crore to Rs 1,83,422 crore in 2021-22.The exports achieved in 2021-22 is the Pharma Sectors best export performance ever and is a remarkable growth ...

Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares. ...

"In order to increase the production of patented drugs manufacturing in the country, both innovation and research is required," Mansukh Mandaviya added.

S Sridhar - The successful implementation of data systems will lead to value-adding analytics that helps reduce healthcare costs, underpinned by better outcomes, , digital india, digitalisation

Reliance Industries may bid for Walgreens Boots Alliance's UK-based Boots business